Background: Patients with advanced gastroesophageal junction cancer (GEJC) have poor survival outcomes, and GEJC-specific data from trials evaluating agents in gastric cancers (GCs) as a whole are lacking. Trifluridine/tipiracil (FTD/TPI) was approved for previously treated metastatic GC or GEJC (mGC/mGEJC) based on results of the phase 3 TAGS trial. Subgroup analyses by primary tumor type (GC or GEJC) in TAGS are reported here.

Methods: Pa tients with mGC/mGEJC treated with  ≥ 2 prior chemotherapy regimens were randomized (2:1) to receive FTD/TPI or placebo, plus best supportive care. A pre-planned sub-analysis was performed to evaluate efficacy and safety outcomes by primary tumor type (GEJC or GC).

Results: Of 507 randomized patients, 145 (29%) had GEJC and 360 (71%) had GC as the primary disease site. Baseline characteristics were generally similar between the GEJC and GC subgroups, except that more patients in the GEJC subgroup had received  ≥ 3 prior regimens (72 vs. 59% in the GC subgroup). Survival benefit with FTD/TPI was observed in both subgroups. The overall survival hazard ratio for FTD/TPI vs placebo was 0.75 (95% CI 0.50-1.11) and 0.67 (95% CI 0.52-0.87) in the GEJC and GC subgroups, respectively. Grade ≥ 3 adverse events of any cause were reported in 75 (77%) and 192 (81%) FTD/TPI-treated patients in the GEJC and GC subgroups, respectively. No new safety concerns were noted with FTD/TPI.

Conclusion: As in patients with GC, FTD/TPI showed an efficacy benefit in patients with GEJC in the TAGS trial, along with demonstrating a manageable safety profile.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205879PMC
http://dx.doi.org/10.1007/s10120-021-01156-xDOI Listing

Publication Analysis

Top Keywords

gejc subgroups
12
patients gejc
12
gejc
10
gastroesophageal junction
8
junction cancer
8
phase tags
8
tags trial
8
primary tumor
8
tumor type
8
type gejc
8

Similar Publications

Article Synopsis
  • The RATIONALE-305 trial found that using tislelizumab with chemotherapy is more effective for treating advanced gastric cancer than using chemotherapy alone.
  • A cost-effectiveness analysis showed that this combination therapy resulted in a gain of 0.31 quality-adjusted life years (QALYs) at an incremental cost-effectiveness ratio (ICER) of $33,876.38 per QALY, which is below China's willingness-to-pay threshold.
  • The study concluded that tislelizumab with chemotherapy is a cost-effective treatment option in the Chinese healthcare context for advanced gastric cancer and gastroesophageal junction adenocarcinoma.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the cost-effectiveness of combining tislelizumab with chemotherapy for treating unresectable gastric or gastroesophageal junction cancer, comparing results in China and the US.
  • In China, the combination treatment is deemed cost-effective, with an incremental cost-effectiveness ratio (ICER) of $37,768.48 per quality-adjusted life year (QALY), marginally below the willingness-to-pay threshold.
  • Conversely, in the US, the ICER is significantly higher at $502,786.22 per QALY, indicating that the combination treatment is not cost-effective there.
View Article and Find Full Text PDF

Background: Immunotherapy offers new hope for improved survival in patients with advanced gastric cancer. Although large randomized controlled trials (RCTs) have been conducted to explore the efficacy and safety of first-line immunotherapy plus chemotherapy versus chemotherapy alone for advanced gastric cancer, the results are not completely consistent. And the strict inclusion criteria of RCTs lead to limited extrapolation.

View Article and Find Full Text PDF

Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China.

Front Pharmacol

September 2024

Department of Pharmacy, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, China.

Background: The Chinese Society of Clinical Oncology (CSCO) has recommended sintilimab plus chemotherapy (SINT + Chemo) as a standard first-line therapy for advanced gastric cancer or gastroesophageal junction cancer (GC/GEJC), based on the proven effectiveness and safety in the ORINT-16 trail. Its cost-effectiveness, however, remains to be evaluated.

Methods: We established a partitioned survival approach (PartSA) model with a 10-year time horizon to determine whether SINT + Chemo (vs.

View Article and Find Full Text PDF

Background: This study compares first-line pembrolizumab plus chemotherapy with chemotherapy alone for patients with HER2-negative advanced gastric cancer (GC) and gastroesophageal junction cancer (GEJC) in China.

Methods: A Markov state-transition model was developed based on the phase 3 randomized KEYNOTE-859 clinical trial data. The health state utility values and direct medical costs were derived from the KEYNOTE-859 clinical trial, the relevant literature, and local charges.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!